OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of “Hold” from Analysts

Shares of OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) have received a consensus rating of “Hold” from the five analysts that are covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $6.3333.

OKYO has been the subject of a number of research analyst reports. Piper Sandler began coverage on OKYO Pharma in a report on Friday, February 20th. They set an “overweight” rating and a $7.00 price objective for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of OKYO Pharma in a research report on Thursday, January 22nd. B. Riley Financial began coverage on OKYO Pharma in a research note on Monday, December 8th. They set a “buy” rating and a $5.00 price target for the company. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of OKYO Pharma in a research note on Thursday, January 29th.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new stake in OKYO Pharma during the third quarter worth approximately $31,000. XTX Topco Ltd purchased a new position in shares of OKYO Pharma in the 4th quarter valued at $36,000. Finally, Renaissance Technologies LLC lifted its holdings in shares of OKYO Pharma by 235.0% during the 4th quarter. Renaissance Technologies LLC now owns 138,000 shares of the company’s stock valued at $286,000 after acquiring an additional 96,800 shares in the last quarter. 2.97% of the stock is owned by institutional investors and hedge funds.

OKYO Pharma Price Performance

OKYO opened at $1.68 on Tuesday. OKYO Pharma has a 1 year low of $1.03 and a 1 year high of $3.35. The company’s 50 day simple moving average is $2.01 and its 200 day simple moving average is $2.11.

OKYO Pharma (NASDAQ:OKYO) last issued its quarterly earnings results on Friday, January 30th. The company reported ($2.28) EPS for the quarter, missing the consensus estimate of ($0.07) by ($2.21). As a group, sell-side analysts anticipate that OKYO Pharma will post -0.17 earnings per share for the current fiscal year.

OKYO Pharma Company Profile

Okyo Pharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for inflammatory and fibrotic diseases. The company’s pipeline is built on proprietary Fc-fusion technology designed to modulate immune responses associated with conditions such as diabetic nephropathy and chronic graft-versus-host disease. Okyo Pharma seeks to address significant unmet medical needs by targeting key cytokine pathways involved in tissue inflammation and fibrosis.

Okyo Pharma’s lead product candidate, OK-101, is an Fc-fusion protein in Phase 2 development for the treatment of diabetic kidney disease.